Who Paid My Doc
Linda Sher
Transplant Surgery Los Angeles, CA Doctor of Osteopathy
NPI 1770518854 CMS profile 1154002
1516 San Pablo St Fl 2, Los Angeles, CA 90033
General payments
$3,441
Research payments
$443,548
Ownership & investment interest
$0
Research they led as principal investigator
$200
Through program year 2025, Linda Sher of Los Angeles, CA is reported in the CMS Open Payments database as having received $3,441 across 16 general payments and $443,548 in research payments paid to them. Separately, studies naming them as principal investigator received $200 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $833 | 7 | |
| 2025 | Research | $105,000 | 12 | |
| 2024 | General | $2,414 | 7 | |
| 2024 | Research | $60,000 | 12 | |
| 2023 | General | $160 | 1 | |
| 2023 | Research | $60,000 | 12 | |
| 2022 | Research | $60,000 | 12 | |
| 2021 | Research | $60,000 | 12 | |
| 2020 | Research | $60,000 | 12 | |
| 2019 | General | $33 | 1 | |
| 2019 | Research | $38,548 | 8 |
Beside peers
- Linda Sher
- Transplant Surgery median
- Middle half of Transplant Surgery
- National median
In program year 2025, general payments to Linda Sher were reported at $833. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.
Show as a table
| Year | Linda Sher | Transplant Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $33 | $203 | $77–$1,249 | $163 |
| 2020 | $0 | $149 | $52–$1,366 | $114 |
| 2021 | $0 | $168 | $73–$2,008 | $132 |
| 2022 | $0 | $213 | $94–$1,464 | $149 |
| 2023 | $160 | $262 | $93–$1,458 | $160 |
| 2024 | $2,414 | $354 | $126–$2,252 | $164 |
| 2025 | $833 | $421 | $116–$2,169 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
96 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Transplant Surgery in California
Elizabeth Squiers
Transplant Surgery · Half Moon Bay, CA
Myron Tong
Transplant Surgery · Pasadena, CA
Robert Redfield
Transplant Surgery · Orange, CA
Yuri Genyk
Transplant Surgery · Los Angeles, CA
Angeles Baquerizo
Transplant Surgery · La Jolla, CA
Navpreet Kaur
Transplant Surgery · Los Angeles, CA
Related records
Transplant Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Transplant Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.